Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease

Lipids in Health and Disease

Review

Sabina Paglialunga¹  Clayton A. Dehn² 

[1] Global Clinical Research, Celerion, 2420 West Baseline Road, 85283, Tempe, AZ, USA;Global Clinical Research, Celerion, 2420 West Baseline Road, 85283, Tempe, AZ, USA;Current affiliation: Umbrella Corporation, San Antonio, TX, USA;

关键词: Stable label isotope;    MIDA;    Fatty acid indexes;    Indirect calorimetry;    Fructose;   

DOI  :  10.1186/s12944-016-0321-5

 received in 2016-03-01, accepted in 2016-08-30,  发布年份 2016

来源: Springer

【 摘 要 】

Non-alcoholic fatty liver disease (NAFLD) is heralded as the next big global epidemic. Hepatic de novo lipogenesis (DNL), the synthesis of new fatty acids from non-lipid sources, is thought to play a pivotal role in the development of NAFLD. While there is currently no NAFLD-specific therapeutic agent available, pharmaceutical drugs aimed at reducing hepatic fat accretion may prove to be a powerful ally in the treatment and management of this disease. With a focus on NAFLD, the present review summarizes current techniques examining DNL from a clinical perspective, and describes the merits and limitations of three commonly used assays; stable-label isotope tracer studies, fatty acid indexes and indirect calorimetry as non-invasive measures of hepatic DNL. Finally, the application of DNL assessments in the pharmacological and nutraceutical treatment of NAFLD/NASH is summarized. In a clinical research setting, measures of DNL are an important marker in the development of anti-NAFLD treatments.

【 授权许可】

CC BY   
© The Author(s). 2016